EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti‐Spike IgG antibodies as correlates of protection against SARS‐CoV‐2 infection in the pre‐Omicron and Omicron era

Lisa Seekircher iD, Manfred Astl, Lena Tschiderer iD, Gregor A Wachter, Julia Penz, Bernhard Pfeifer, Andreas Huber, Pedro M Afonso, Manfred Gaber, Harald Schennach, Anita Siller iD, Peter Willeit iD

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29839 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Lisa Seekircher und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, Innsbruck, …. Hauptthemen laut MEDLINE: Immunoglobulin G, SARS-CoV-2, Antibodies, Viral, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Hospital Innsbruck, Federal State of Tyrol.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti‐Spike IgG antibodies against SARS‐CoV‐2, which are elicited by vaccination and infection, are correlates of protection against infection with pre‐Omicron variants. Whether this association can be generalized to infections with Omicron variants is unclear. We conducted a retrospective cohort study with 8457 blood donors in Tyrol, Austria, analyzing 15,340 anti‐Spike IgG antibody measurements from March 2021 to December 2022 assessed by Abbott SARS‐CoV‐2 IgG II chemiluminescent microparticle immunoassay. Using a Bayesian joint model, we estimated antibody trajectories and adjusted hazard ratios for incident SARS‐CoV‐2 infection ascertained by self‐report or seroconversion of anti‐Nucleocapsid antibodies. At the time of their earliest available anti‐Spike IgG antibody measurement (median November 23, 2021), participants had a median age of 46.0 years (IQR 32.8–55.2), with 45.3% being female, 41.3% having a prior SARS‐CoV‐2 infection, and 75.5% having received at least one dose of a COVID‐19 vaccine. Among 6159 participants with endpoint data, 3700 incident SARS‐CoV‐2 infections with predominantly Omicron sublineages were recorded over a median of 8.8 months (IQR 5.7–12.4). The age‐ and sex‐adjusted hazard ratio for SARS‐CoV‐2 associated with having twice the anti‐Spike IgG antibody titer was 0.875 (95% credible interval 0.868–0.881) overall, 0.842 (0.827–0.856) during 2021, and 0.884 (0.877–0.891) during 2022 (all p < 0.001). The associations were similar in females and males (P interaction = 0.673) and across age (P interaction = 0.590). Higher anti‐Spike IgG antibody titers were associated with reduced risk of incident SARS‐CoV‐2 infection across the entire observation period. While the magnitude of association was slightly weakened in the Omicron era, anti‐Spike IgG antibody continues to be a suitable correlate of protection against newer SARS‐CoV‐2 variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin GSARS-CoV-2Antibodies, ViralCOVID-19Spike Glycoprotein, CoronavirusHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAustriaCOVID-19 VaccinesSeroconversionBayes Theorem

Stichwörter der Autor:innen

Bayesian joint modelanti‐Spike IgG antibody trajectoriesblood donorscorrelate of protection against infectionincident SARS‐CoV‐2 infectionpre‐Omicron and Omicron era

Substanzen

Immunoglobulin GAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19 Vaccines

Autor:innen und Institutionen

  • Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, Innsbruck, Austria.
  • Central Institute for Blood Transfusion and Immunology, University Hospital Innsbruck, Tirol Kliniken GmbH, Innsbruck, Austria.
  • Tyrolean Federal Institute for Integrated Care, Tirol Kliniken GmbH, Innsbruck, Austria.
  • Division for Healthcare Network and Telehealth, UMIT-Private University for Health Sciences, Medical Informatics and Technology GmbH, Hall, Austria.
  • Department of Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.

ORCID-Profile: Lisa Seekircher, Lena Tschiderer, Anita Siller, Peter Willeit

Förderung

  • University Hospital Innsbruck
  • Federal State of Tyrol

Zitieren

APA

Seekircher, L., Astl, M., Tschiderer, L., Wachter, G. A., Penz, J., Pfeifer, B., Huber, A., Afonso, P. M., Gaber, M., Schennach, H., Siller, A., & Willeit, P. (2024). Anti‐Spike IgG antibodies as correlates of protection against SARS‐CoV‐2 infection in the pre‐Omicron and Omicron era. Journal of Medical Virology. https://doi.org/10.1002/jmv.29839

Vancouver

Seekircher L, Astl M, Tschiderer L, Wachter GA, Penz J, Pfeifer B, et al. Anti‐Spike IgG antibodies as correlates of protection against SARS‐CoV‐2 infection in the pre‐Omicron and Omicron era. Journal of Medical Virology. 2024. doi:10.1002/jmv.29839

BibTeX
@article{Seekircher2024,
  author = {Seekircher, Lisa and Astl, Manfred and Tschiderer, Lena and Wachter, Gregor A and Penz, Julia and Pfeifer, Bernhard and Huber, Andreas and Afonso, Pedro M and Gaber, Manfred and Schennach, Harald and Siller, Anita and Willeit, Peter},
  title = {Anti‐Spike IgG antibodies as correlates of protection against SARS‐CoV‐2 infection in the pre‐Omicron and Omicron era},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29839}
}
Kostenlos starten →